KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cel...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
18 June 2021
|
| In: |
Blood cancer journal
Year: 2021, Volume: 11, Issue: 6, Pages: 1-9 |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/s41408-021-00507-2 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41408-021-00507-2 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41408-021-00507-2 
|
| Author Notes: | Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal and David S. Siegel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1767400691 | ||
| 003 | DE-627 | ||
| 005 | 20260129092227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210819s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-021-00507-2 |2 doi | |
| 035 | |a (DE-627)1767400691 | ||
| 035 | |a (DE-599)KXP1767400691 | ||
| 035 | |a (OCoLC)1341420930 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Jagannath, Sundar |e VerfasserIn |0 (DE-588)140619119 |0 (DE-627)703734555 |0 (DE-576)319136566 |4 aut | |
| 245 | 1 | 0 | |a KarMMa-RW |b comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |c Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal and David S. Siegel |
| 264 | 1 | |c 18 June 2021 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.08.2021 | ||
| 520 | |a Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM patients were merged into a single data model and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting. Endpoints included overall response rate (ORR; primary), rate of very good partial response or better (≥VGPR), progression-free survival (PFS), and overall survival (OS). Of 1949 real-world triple-class exposed RRMM patients, 190 received subsequent (index) line of therapy and met KarMMa eligibility criteria (Eligible RRMM cohort). With a median follow-up of 13.3 months in KarMMa and 10.2 months in Eligible RRMM, ORR, and ≥VGPR were significantly improved in KarMMa versus Eligible RRMM (ORR, 76.4% vs 32.2%; ≥VGPR, 57.9% vs 13.7%; both P < 0.0001) as were PFS (11.6 vs 3.5 months; P = 0.0004) and OS (20.2 vs 14.7 months; P = 0.0006). This study demonstrated that ide-cel significantly improved responses and survival compared with currently available therapies in triple-class exposed RRMM. | ||
| 700 | 1 | |a Lin, Yi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Reece, Donna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nooka, Ajay |e VerfasserIn |4 aut | |
| 700 | 1 | |a Senin, Alicia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rodriguez-Otero, Paula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Powles, Ray |e VerfasserIn |4 aut | |
| 700 | 1 | |a Matsue, Kosei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shah, Nina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anderson, Larry D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Streetly, Matthew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wilson, Kimberly |e VerfasserIn |4 aut | |
| 700 | 1 | |a Le, Hoa Van |e VerfasserIn |4 aut | |
| 700 | 1 | |a Swern, Arlene S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Agarwal, Amit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siegel, David S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d [London] : Springer Nature, 2011 |g 11(2021), 6, Artikel-ID 116, Seite 1-9 |h Online-Ressource |w (DE-627)655134174 |w (DE-600)2600560-8 |w (DE-576)339571802 |x 2044-5385 |7 nnas |a KarMMa-RW comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:6 |g elocationid:116 |g pages:1-9 |g extent:9 |a KarMMa-RW comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41408-021-00507-2 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41408-021-00507-2 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20210819 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1767400691 |e 3969943965 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1038/s41408-021-00507-2"],"eki":["1767400691"]},"recId":"1767400691","relHost":[{"language":["eng"],"part":{"extent":"9","volume":"11","text":"11(2021), 6, Artikel-ID 116, Seite 1-9","issue":"6","pages":"1-9","year":"2021"},"title":[{"title_sort":"Blood cancer journal","title":"Blood cancer journal"}],"note":["Gesehen am 17.07.24"],"pubHistory":["1.2011-"],"origin":[{"dateIssuedDisp":"2017-","publisher":"Springer Nature ; Nature Publ. Group","dateIssuedKey":"2017","publisherPlace":"[London] ; London [u.a.]"}],"disp":"KarMMa-RW comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaBlood cancer journal","type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"655134174","id":{"eki":["655134174"],"zdb":["2600560-8"],"issn":["2044-5385"]}}],"name":{"displayForm":["Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal and David S. Siegel"]},"physDesc":[{"extent":"9 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 19.08.2021"],"origin":[{"dateIssuedDisp":"18 June 2021","dateIssuedKey":"2021"}],"title":[{"subtitle":"comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","title_sort":"KarMMa-RW","title":"KarMMa-RW"}],"language":["eng"],"person":[{"given":"Sundar","role":"aut","display":"Jagannath, Sundar","family":"Jagannath"},{"role":"aut","given":"Yi","family":"Lin","display":"Lin, Yi"},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","role":"aut","given":"Hartmut"},{"family":"Reece","display":"Reece, Donna","role":"aut","given":"Donna"},{"display":"Nooka, Ajay","family":"Nooka","role":"aut","given":"Ajay"},{"display":"Senin, Alicia","family":"Senin","given":"Alicia","role":"aut"},{"family":"Rodriguez-Otero","display":"Rodriguez-Otero, Paula","role":"aut","given":"Paula"},{"given":"Ray","role":"aut","family":"Powles","display":"Powles, Ray"},{"given":"Kosei","role":"aut","display":"Matsue, Kosei","family":"Matsue"},{"role":"aut","given":"Nina","display":"Shah, Nina","family":"Shah"},{"family":"Anderson","display":"Anderson, Larry D.","role":"aut","given":"Larry D."},{"role":"aut","given":"Matthew","display":"Streetly, Matthew","family":"Streetly"},{"given":"Kimberly","role":"aut","family":"Wilson","display":"Wilson, Kimberly"},{"family":"Le","display":"Le, Hoa Van","given":"Hoa Van","role":"aut"},{"given":"Arlene S.","role":"aut","family":"Swern","display":"Swern, Arlene S."},{"display":"Agarwal, Amit","family":"Agarwal","role":"aut","given":"Amit"},{"role":"aut","given":"David S.","display":"Siegel, David S.","family":"Siegel"}]} | ||
| SRT | |a JAGANNATHSKARMMARW1820 | ||